Formycon

Formycon Equity

The The Equity of Formycon (FYB.DE) as of Nov 19, 2026 is 399.14 M EUR. In the previous year, The Equity was 461.84 M EUR — a change of -13.58% (lower).

Equity

399.14 MEUR

YoY

-13.58%

Last updated:

In 2025, Formycon's equity was 399.14 M EUR, a -13.58% increase from the 461.84 M EUR equity in the previous year.

The Formycon Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
33.24 M EUR
Jan 1, 2019
48.21 M EUR
Jan 1, 2020
68.04 M EUR
Jan 1, 2021
55.89 M EUR
Jan 1, 2022
356.58 M EUR
Jan 1, 2023
502.75 M EUR
Jan 1, 2024
461.84 M EUR
Jan 1, 2025
399.14 M EUR
The Formycon Equity history
YEAREquityYoY
399.14 MEUR-13.58%
461.84 MEUR-8.14%
502.75 MEUR+40.99%
356.58 MEUR+537.99%
55.89 MEUR-17.85%
68.04 MEUR+41.12%
48.21 MEUR+45.04%
33.24 MEUR+30.13%
25.54 MEUR+22.27%
20.89 MEUR-16.00%
24.87 MEUR+89.69%
13.11 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Formycon Stock analysis

What does Formycon do? Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Formycon's Equity

Formycon's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Formycon's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Formycon's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Formycon's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Formycon’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Formycon stock

The Equity of Formycon is 399.14 M EUR in 2025.

The Equity of Formycon changed from 461.84 M EUR to 399.14 M EUR, representing a -13.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Formycon since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Formycon historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Formycon

All Key Metrics — Formycon